BAAR, Switzerland, June 30, 2026
Novocure has achieved a significant milestone in cancer treatment with the CE Mark approval for Optune Pax®, its innovative Tumor Treating Fields (TTFields) therapy for adults with locally advanced pancreatic cancer of exocrine origin. The approval allows the wearable medical device to be used in combination with gemcitabine and nab-paclitaxel in accordance with European treatment guidelines, providing a new therapeutic option for one of the deadliest forms of cancer. The CE Mark is supported by positive results from the pivotal Phase 3 PANOVA-3 clinical trial, which demonstrated statistically significant improvements in overall survival and pain progression, reinforcing the growing role of non-invasive, device-based cancer therapies.
Phase 3 PANOVA-3 Trial Demonstrates Survival Benefit
The PANOVA-3 study enrolled 571 patients with locally advanced pancreatic cancer in an international, prospective, randomized Phase 3 clinical trial evaluating Optune Pax plus gemcitabine and nab-paclitaxel versus chemotherapy alone. The trial successfully met its primary endpoint by demonstrating a statistically significant improvement in median overall survival (mOS). Patients receiving the combination therapy achieved a median overall survival of 16.2 months, compared with 14.2 months for chemotherapy alone in the intent-to-treat population. In the modified intent-to-treat population, overall survival increased to 18.3 months, compared with 15.1 months in the control group, representing a 3.2-month improvement.
The treatment also improved the one-year survival rate, highlighting the potential of Tumor Treating Fields to complement standard chemotherapy in extending patient survival. These findings represent an important advance in the treatment landscape, where effective options have historically remained limited due to the aggressive nature of pancreatic cancer.
Wearable TTFields Therapy Delays Pain Progression and Preserves Quality of Life
Advertisement
Beyond improving survival outcomes, Optune Pax demonstrated meaningful clinical benefits by significantly delaying pain progression, a major challenge for patients living with advanced pancreatic cancer. Patients treated with the device experienced a median time to pain progression of 15.2 months, compared with 9.1 months in the chemotherapy-alone group, representing a 6.1-month improvement. Quality-of-life assessments further showed longer deterioration-free survival across multiple patient-reported outcomes, including global health status, pancreatic pain, digestive symptoms, emotional function, and fatigue.
The therapy was also well tolerated, with no unexpected safety concerns. Most treatment-related adverse events consisted of mild to moderate skin reactions beneath the wearable arrays, while systemic toxicities remained comparable to chemotherapy alone. According to Novocure, Tumor Treating Fields work by delivering alternating electric fields that selectively disrupt cancer cell division and survival without significantly affecting healthy tissue, offering a unique non-invasive mechanism for treating solid tumors.
European Approval Strengthens Novocure’s Oncology Portfolio
The CE Mark represents a major commercial and regulatory milestone for Novocure, enabling the company to introduce Optune Pax across European markets beginning with Germany in the coming weeks. The approval follows the device’s U.S. FDA approval in February 2026, further expanding global access to the company’s innovative TTFields technology. Pancreatic cancer remains one of the most lethal malignancies worldwide, with limited treatment options and poor long-term survival, making innovative approaches increasingly important.
Novocure believes the approval reinforces the clinical value of TTFields therapy as an effective addition to standard oncology care and strengthens its growing portfolio of device-based cancer treatments targeting multiple aggressive tumor types. As healthcare providers continue seeking therapies that improve survival while maintaining patient quality of life, Optune Pax is positioned to become an important new option in the management of locally advanced pancreatic cancer.
Source: Novocure press release
